Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. company information, Employees & Contact Information

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing. More information is available at www.armatapharma.com

Company Details

Employees
67
Founded
-
Address
5005 Mcconnell Ave, Los Angeles,california 90066,united States
Phone
310-665-2928
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Los Angeles, California
Looking for a particular Armata Pharmaceuticals, Inc. employee's phone or email?

Armata Pharmaceuticals, Inc. Questions

News

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Finansavisen

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Finansavisen

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - PR Newswire

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update PR Newswire

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ - Sahm

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ Sahm

Bacteriophage Therapeutics Pioneer Armata Pharmaceuticals to Showcase Pipeline at Major Investment Conference - Stock Titan

Bacteriophage Therapeutics Pioneer Armata Pharmaceuticals to Showcase Pipeline at Major Investment Conference Stock Titan

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - PR Newswire

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 PR Newswire

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - PR Newswire

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia PR Newswire

Armata Pharmaceuticals Announces Chief Executive Officer Transition - PR Newswire

Armata Pharmaceuticals Announces Chief Executive Officer Transition PR Newswire

Top Armata Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant